Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy

Outcomes in ALK+ NSCLC Patients Receiving Immuno-Oncology Therapy

Cancer-News

6 months
13 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Mohammed Jahanzeb, MD explains the design of the study examining real-world treatment patterns and outcomes in U.S. ALK+ NSCLC patients receiving immuno-oncology therapy.
Up Next Autoplay